iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F22%3A00561885" target="_blank" >RIV/67985904:_____/22:00561885 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/22:10446929 RIV/00216208:11140/22:10446929 RIV/00216224:14310/22:00128903

Result on the web

<a href="https://www.mdpi.com/2075-4426/12/9/1485" target="_blank" >https://www.mdpi.com/2075-4426/12/9/1485</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/jpm12091485" target="_blank" >10.3390/jpm12091485</a>

Result language

angličtina

Original language name

iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

Original language description

In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing animal models, ethical issues, and lack of resemblance with human disease. Due to poor initial screening and assessment of the molecules, more than 90% of drugs fail during the final step of the human clinical trial. To overcome these limitations, a new approach has been developed based on induced pluripotent stem cells (iPSCs). The discovery of iPSCs has provided a new roadmap for clinical translation research and regeneration therapy. In this article, we discuss the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer's disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. We have observed that Parkinson's disease scored highest, followed by Alzheimer's disease. Furthermore, we also explored recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

<a href="/en/project/NU20-09-00437" target="_blank" >NU20-09-00437: Identification of changes in glutamatergic pathways specific for sporadic form of Alzheimer's disease in human neurons and astrocytes induced from patient's cells</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Personalized Medicine

ISSN

2075-4426

e-ISSN

2075-4426

Volume of the periodical

12

Issue of the periodical within the volume

9

Country of publishing house

CH - SWITZERLAND

Number of pages

18

Pages from-to

1485

UT code for WoS article

000857061800001

EID of the result in the Scopus database

2-s2.0-85138617022